N@N

Valeant Pharmaceuticals International, GlaxoSmithKline, Pfizer, UCB Pharma and Johnson & Johnson

_{//health-fitness.news-articles.net/content/2010/ .. kline-pfizer-ucb-pharma-and-johnson-johnson.html}
^{Published in Health and Fitness on Monday, December 6th 2010 at 7:10 GMT by Market Wire}  

CHICAGO--([ BUSINESS WIRE ])--Zacks.com Analyst Blog features: Valeant Pharmaceuticals International (NYSE: [ VRX ]), GlaxoSmithKline plc (NYSE: [ GSK ]), Pfizer Inc. (NYSE: [ PFE ]), UCB Pharma (OTC: [ UCBJF ]) and Johnson & Johnson (NYSE: [ JNJ ]).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=4579 ]

Here are highlights from Fridaya™s Analyst Blog:

Setback for Valeant Epilepsy Drug

Valeant Pharmaceuticals International (NYSE: [ VRX ]) and GlaxoSmithKline plc (NYSE: [ GSK ]) recently announced that the US Food and Drug Administration (FDA) issued a complete response letter (CRL) for the new drug application (NDA) for their epilepsy candidate, ezogabine. The regulatory body said that the CRL was for non-clinical reasons. Valeant and Glaxo are currently evaluating the letter and plan to file a response to the FDA in 2011.

The companies are seeking approval for ezogabine both in the US and the EU for the treatment of adults with partial-onset seizures. The NDA was submitted to the FDA on October 30, 2009, while the Marketing Authorization Application was submitted to the European Medicines Evaluation Agency on November 17, 2009.

Ezogabinea™s Regulatory Pathway

Earlier, in August, Glaxo and Valeant had received a positive recommendation from an FDA advisory panel regarding ezogabine. The FDAa™s Peripheral and Central Nervous System Drugs Advisory Committee had reviewed the safety and efficacy of the drug and voted unanimously in favor of ezogabinea™s efficacy for the treatment of partial-onset seizures in adults where other treatments failed. However, later during the month, the FDA extended the review date for the candidate by three months.

Ezogabine has been developed under a worldwide license and collaboration agreement between Glaxo and Valeant and the FDA approval would be a major boost for both companies, particularly for Valeant.

Competitive Scenario

Currently available epilepsy treatments include drugs like Pfizer Inc.a™s (NYSE: [ PFE ]) Neurontin and Lyrica, Glaxoa™s Lamictal, UCB Pharmaa™s (OTC: [ UCBJF ]) Keppra and Johnson & Johnsona™s (NYSE: [ JNJ ]) Topamax. We believe that ezogabine, once approved, should be able to carve a niche for itself due to its differentiated mechanism of action.

Neutral on Valeant

We currently have a Neutral recommendation on Valeant. The company faces major challenges with its neurology product Diastat and HIV drug ribavirin exposed to generic competition. We believe the company needs to enter into suitable deals in order to compensate for the loss of revenues resulting from the genericization of Diastat and ribavirin.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=5514 ].

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: [ http://at.zacks.com/?id=5516 ]

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=4580 ].

Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.

Follow us on Twitter: [ http://twitter.com/ZacksResearch ]

Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.